Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma

Pontine Glioma Clinical Trial

Official title:
A Phase II, Open-label, Multi-center Study of Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma.

Status Terminated

Clinical Trial Summary

The purpose of this research study is to evaluate an investigational drug (Vismodegib) for Pontine Glioma that is growing or has come back (reoccurred). This study will look at the tumors response to the study drug, Vismodegib, and will also look at the safety and tolerability of Vismodegib. Vismodegib has been tested in multiple adult clinical trials and one pediatric trial. Laboratory testing in pontine gliomas suggests that this drug may be effective in treating this disease.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01774253
Study type	Interventional
Source	Milton S. Hershey Medical Center
Contact
Status	Terminated
Phase	Phase 2
Start date	May 2013
Completion date	October 2015

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT00994071` - A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	Phase 1